文献速递肾癌与肾肿瘤

改良格拉斯哥预后评分动态变化对局限性透明细胞肾细胞癌切除术后患者的评估

Dynamic Evaluation of the Modified Glasgow Prognostic Scale in Patients With Resected, Localized Clear Cell Renal Cell Carcinoma.
PubMed 文献 · Urology · 2020-04-12

本研究回顾性纳入2005至2018年接受肾切除术且术前mGPS=0的局限性透明细胞肾细胞癌患者,评估术前60天至术后1年mGPS变化与生存结局的关系。

要点

  • 术后mGPS升高与ccRCC肾切除术后死亡和复发风险增加独立相关。
  • mGPS动态变化可能辅助识别侵袭性较强或复发风险较高的患者。
  • mGPS廉价、经验证且可重复,或有助于术后风险分层与患者咨询。

核心结论

  • 肾切除术后mGPS升高的局限性ccRCC患者死亡和癌症复发风险更高。

研究设计与样本

  • 回顾性队列研究,纳入2005至2018年接受肾切除术且术前mGPS=0的局限性ccRCC患者313例,中位随访20.2个月。

临床怎么用

  • 术后评估mGPS动态变化可能有助于识别高死亡和复发风险的ccRCC患者。
  • 可利用mGPS变化辅助患者咨询癌症复发风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the relationship between dynamic changes in the modified Glasgow Prognostic Scale (mGPS) and postnephrectomy survival among localized clear cell renal cell carcinoma (ccRCC) patients. METHODS: We retrospectively identified patients who underwent nephrectomy for localized ccRCC with preoperative mGPS = 0 from 2005 to 2018. The primary exposure of interest was ΔmGPS between 2 points - 60 days prior to surgery and 1 year after surgery. We assessed the relationship between ΔmGPS and survival outcomes. Kaplan-Meier curves were generated to determine survival estimates and Cox proportional hazards models were fit to estimate hazard ratios (HRs). Multivariable models were constructed using both ΔmGPS and clinical variables known to be associated with differences in survival. RESULTS: We identified 313 patients for our analytic cohort with a median follow-up time of 20.2 months. Thirty-seven (11.9%) patients died and 39 (12.54%) showed recurrence during follow-up. Two hundred sixty-three (84.6%) patients had unchanged mGPS before and after surgery, while 48 (15.4%) patients showed an increase in postoperative mGPS from preoperative mGPS. Compared to patients with unchanged mGPS, patients with a higher postoperative mGPS had an increased risk of death (HR = 3.05 [1.39-6.68], P = .005) and recurrence (HR = 2.98 [1.34-6.64], P = .008). CONCLUSION: Patients with an increase in mGPS following nephrectomy for ccRCC were more likely to die and experience cancer recurrence. Assessing dynamic changes in this cheap, validated, and reproducible test may be useful in identifying patients at higher risk for more aggressive disease or for counseling patients regarding risk of cancer recurrence.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Patil D, Le TL, Bens KB, et al. Dynamic Evaluation of the Modified Glasgow Prognostic Scale in Patients With Resected, Localized Clear Cell Renal Cell Carcinoma. Urology. 2020. PMID: 32294483. doi:10.1016/j.urology.2020.03.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。